GlobeNewswire

Remedy Plan Therapeutics Announces Multiple Presentations at the AACR Annual Meeting 2026
16/04/2026
GAITHERSBURG, Md., April 16, 2026 (GLOBE NEWSWIRE) -- Remedy Plan Therapeutics, a clinical-stage biotechnology company developing novel therapies that target fundamental metabolic vulnerabilities in disease, today [...]
Radiopharm Theranostics Completes Enrollment in U.S. Phase 2b Imaging Trial of RAD 101 for Diagnosis of Brain Metastases
16/04/2026
Interim data to date showed 90% concordance with MRI (the primary endpoint) Clinical trial readout (Primary endpoint) expected in June 2026 Plans to advance RAD 101 into U.S. Phase 3 pivotal trial SYDNEY, April 16, 2026 [...]
Beamion LUNG-1 study results for zongertinib in treatment-naïve patients with HER2-mutant advanced NSCLC published in The New England Journal of Medicine
16/04/2026
This press release is not intended for US or UK media. Ingelheim, Germany and Ridgefield, Conn. Boehringer Ingelheim today announced that The New England Journal of Medicine (NEJM) published results from the Phase 1b [...]
Eton Pharmaceuticals Announces CFO Succession Plan
16/04/2026
Experienced pharmaceutical executive Judith M. Matthews to assume CFO role on June 1st DEER PARK, Ill., April 16, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (“Eton” or the “Company”) (Nasdaq: ETON), an [...]
Aclarion Secures U.S. Patent Advancing Scalable, AI-Driven Assessment of Chronic Low Back Pain
16/04/2026
Patent covers use of AI in workflows of future products to accelerate company’s ability to scale and enhance already strong gross margins Expands intellectual property portfolio to 64 issued and pending patents [...]
Aligos Therapeutics Enters into Exclusive License Deal with Xiamen Amoytop Biotech Co., Ltd. to Develop and Commercialize Pevifoscorvir Sodium in Greater China for Chronic Hepatitis B Virus Infection
16/04/2026
Aligos to receive an upfront payment of $25M USD Up to $420M USD in clinical, regulatory, and sales milestones along with tiered, high single-digit royalties Amoytop to fund its development program in Greater China [...]
Aicuris Receives FDA Priority Review for Pritelivir NDA and Presents New Phase 3 Data at ESCMID 2026
16/04/2026
The U.S. Food and Drug Administration has granted Priority Review for Aicuris’ New Drug Application for pritelivir, a novel helicase primase inhibitor developed to treat refractory herpes simplex virus infections, with [...]
Alethio Therapeutics Unveils ATX‑011, a Breakthrough, Mutation‑Agnostic Antibody for Treating Essential Thrombocythemia – a c.$2B Market, and Strengthens Leadership to Accelerate Path to IND
16/04/2026
Oxford, UK – 16th April 2026 - Alethio Therapeutics, a biopharmaceutical company developing novel treatments for myeloproliferative neoplasms (MPN), today announced the unveiling of ATX‑011, a first‑in‑class, mutation‑ [...]
Roquette Successfully Prices its Hybrid Notes Issuance for an Amount of 600 million Euros
16/04/2026
Roquette Successfully Prices its Hybrid Notes Issuance for an Amount of 600 million Euros Lille, 16 April, 2026 – Roquette, a global leader of plant-based ingredients and pharmaceutical excipients for the health and [...]
Roquette réalise avec succès son émission obligataire hybride, pour un montant de 600 millions d'euros
16/04/2026
Roquette réalise avec succès son émission obligataire hybride, pour un montant de 600 millions d'euros Lille, le 16 avril 2026 - Roquette, un leader mondial des ingrédients d'origine végétale et un fournisseur majeur d’ [...]
Freya Biosciences announces positive Phase 1 first-in-human data with FB301 for IVF-related embryo implantation failure
16/04/2026
FB301 was safe and well tolerated in healthy female subjects, with all primary and secondary endpoints met Clinically meaningful microbiome modulation observed, including significant improvement up to 6-month follow-up [...]
CancerVax to Target Colorectal Cancer Following Recent Biodistribution Breakthroughs
16/04/2026
New findings support hypothesis that current nanoparticle designed for pancreatic and liver cancers could also work for colorectal cancer Lehi, Utah, April 16, 2026 (GLOBE NEWSWIRE) -- CancerVax, Inc., the developer of [...]
STORM Therapeutics Secures $56 Million Series C Financing and Doses First Patient in Phase 2 Sarcoma Trial of STC‑15
16/04/2026
The proceeds will support the advancement of STC-15 in a Phase 2 study in select sarcoma indications First ‑ in ‑ class METTL3 inhibitor reprograms malignant progenitor cells by modulating mRNA methylation CAMBRIDGE, [...]
TME Pharma Announces Publication of NOX-A12 “Triple Therapy” Phase 1/2 Expansion Arm A Findings from GLORIA trial in Nature Communications
16/04/2026
TME Pharma Announces Publication of NOX-A12 “Triple Therapy” Phase 1/2 Expansion Arm A Findings from GLORIA trial in Nature Communications Berlin, Germany , April 16, 2026, 08.00am CET – TME Pharma N.V. (Euronext Growth [...]
TME PHARMA ANNONCE LA PUBLICATION DANS *NATURE COMMUNICATIONS* DES RÉSULTATS DE L'ESSAI GLORIA CONCERNANT LE VOLET D'EXTENSION A DE PHASE 1/2 DE LA « TRIPLE THÉRAPIE » NOX-A12
16/04/2026
TME PHARMA ANNONCE LA PUBLICATION DANS *NATURE COMMUNICATIONS* DES RÉSULTATS DE L'ESSAI GLORIA CONCERNANT LE VOLET D'EXTENSION A DE PHASE 1/2 DE LA « TRIPLE THÉRAPIE » NOX-A12 Berlin, Allemagne, le 16 avril 2026, 8 h 00 [...]
Greywolf Therapeutics appoints Edwin Moses as Chair
16/04/2026
OXFORD, United Kingdom, April 16, 2026 (GLOBE NEWSWIRE) -- Greywolf Therapeutics, a clinical-stage biotech company advancing novel antigen modulation treatments for cancer and autoimmune diseases, has appointed Edwin [...]
Pharming Group announces the 2026 Annual General Meeting of Shareholders
16/04/2026
Leiden, the Netherlands, April 16, 2026: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM / Nasdaq: PHAR) today announced that the Company’s 2026 Annual General Meeting of Shareholders (the “ [...]
Eurobio Scientific signe un accord définitif en vue de l'acquisition de la division « Lab Products » de CareDx dédiée à la transplantation
16/04/2026
EUROBIO SCIENTIFIC SIGNE UN ACCORD DÉFINITIF EN VUE DE L'ACQUISITION DE LA DIVISION « LAB PRODUCTS 1 » DE CAREDX DÉDIÉE À LA TRANSPLANTATION L'acquisition du portefeuille « Lab Products » de CareDx ouvre de nouvelles [...]
Eurobio scientific signs definitive agreement to acquire CareDx’s transplant Lab Product division
16/04/2026
EUROBIO SCIENTIFIC SIGNS DEFINITIVE AGREEMENT TO ACQUIRE CAREDX’s TRANSPLANT LAB PRODUCT DIVISION Acquisition of CareDx’s ‘lab products’ portfolio creates new opportunities for growth and innovation in the fast growing [...]

Pages

Other news

Test 2

Lorem ipsum

Test 1

Lorem upsum